NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis → The Single Biggest Breakthrough of the Decade (From Porter & Company) (Ad) Free AEZS Stock Alerts $6.44 -0.16 (-2.42%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$6.40▼$6.6850-Day Range$6.45▼$10.2552-Week Range$5.44▼$12.80Volume5,157 shsAverage Volume6,709 shsMarket Capitalization$7.80 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Aeterna Zentaris alerts: Email Address Aeterna Zentaris MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside831.0% Upside$60.00 Price TargetShort InterestHealthy0.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.67 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAeterna Zentaris has received no research coverage in the past 90 days.Read more about Aeterna Zentaris' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.57% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeterna Zentaris has recently increased by 171.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 3.0 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.Search Interest1 people have searched for AEZS on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.73% of the stock of Aeterna Zentaris is held by institutions.Read more about Aeterna Zentaris' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aeterna Zentaris' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMillions of Unsuspecting Americans Could be Wiped Out…America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. About Aeterna Zentaris Stock (NASDAQ:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesJune 14 at 3:38 AM | americanbankingnews.comShort Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Expands By 171.9%June 13 at 9:10 AM | globenewswire.comAeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyJune 10, 2024 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.comJune 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to ShareholdersJune 3, 2024 | globenewswire.comAeterna Zentaris and Ceapro Complete Merger TransactionMay 29, 2024 | globenewswire.comAeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption DateMay 27, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Announces Details Regarding Transaction with CeaproMay 17, 2024 | finance.yahoo.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 17, 2024 | globenewswire.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 15, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 14, 2024 | washingtonpost.comAeterna Zentaris: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comAeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comAeterna Zentaris Announces Effective Date of Share ConsolidationApril 28, 2024 | finance.yahoo.com12 ChatGPT Penny Stock Picks Right NowApril 2, 2024 | theglobeandmail.comAuxly Cannabis Group: Top 10 Undervalued Healthcare Sector Stocks on TSX (XLY)March 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 27, 2024 | benzinga.comAEterna Zentaris: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comAeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyMarch 13, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsMarch 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 28, 2024 | thestreet.comAeterna Zentaris Inc.February 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 15, 2024 | globenewswire.comAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproNovember 14, 2023 | morningstar.comAEterna Zentaris Inc AEZSNovember 9, 2023 | msn.comAeterna Zentaris GAAP EPS of -$0.85See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/14/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+831.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($14.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-760.32% Pretax Margin-760.28% Return on Equity-83.45% Return on Assets-45.76% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.93 Sales & Book Value Annual Sales$4.50 million Price / Sales1.73 Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book0.43Miscellaneous Outstanding Shares1,210,000Free Float1,213,000Market Cap$7.80 million OptionableNo Data Beta1.60 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsCorrevio PharmaNASDAQ:CORVVYNE TherapeuticsNASDAQ:VYNENeoleukin TherapeuticsNASDAQ:NLTXProMIS NeurosciencesNASDAQ:PMNLisata TherapeuticsNASDAQ:LSTAView All Competitors AEZS Stock Analysis - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for Aeterna Zentaris' stock. Their AEZS share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 831.0% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2024? Aeterna Zentaris' stock was trading at $7.44 at the start of the year. Since then, AEZS stock has decreased by 13.4% and is now trading at $6.4450. View the best growth stocks for 2024 here. Are investors shorting Aeterna Zentaris? Aeterna Zentaris saw a increase in short interest in May. As of May 31st, there was short interest totaling 17,400 shares, an increase of 171.9% from the May 15th total of 6,400 shares. Based on an average daily volume of 9,400 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.6% of the company's stock are short sold. View Aeterna Zentaris' Short Interest. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative trailing twelve-month return on equity of 83.45% and a negative net margin of 760.32%. When did Aeterna Zentaris' stock split? Aeterna Zentaris's stock reverse split on Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEZS) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredMillions of Unsuspecting Americans Could be Wiped Out…America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economi...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.